Wafa Tombari | Vaccines | Best Researcher Award

Published on by Infectious

Assist. Prof. Dr. Wafa Tombari | Vaccines | Best Researcher Award

Assistant Professor | University Hospital of Sahloul | Tunisia

Dr. Wafa Tombari, Ph.D., is an accomplished Assistant Professor and Research Scientist at the University Hospital of Sahloul, Sousse, specializing in infectious diseases with a focus on virology, vaccine development, and antimicrobial resistance. She holds a Doctoral Diploma in Biology from the Faculty of Sciences in Tunisia, a Master of Science in Microbiology, and a Certificate of Complementary Studies in Statistics and Epidemiological Methods from the Faculty of Medicine in Tunisia. With a distinguished academic and research career, Dr. Tombari has served as an Assistant Professor at both the High Institute of Medical Technologies and the University Hospital of Sahloul, where she has successfully led and collaborated on numerous national and international research projects. Her research integrates molecular biology, bioinformatics, and immunoinformatics to develop computational approaches for vaccine design, antiviral therapeutics, and the study of bacterial resistance mechanisms. She has authored several peer-reviewed publications in reputable international journals, including studies on mRNA-based vaccines for rabies virus and molecular characterization of antimicrobial resistance in Staphylococcus species, highlighting her contributions to advancing biomedical innovation. Beyond her research, Dr. Tombari plays an active role in student mentorship, curriculum development, and scientific outreach, fostering collaboration and innovation within the academic community. Her expertise extends to reverse vaccinology, molecular cloning, and phylogenetic analysis, reflecting her multidisciplinary approach to infectious disease research. Dr. Tombari’s scholarly achievements and professional dedication exemplify her commitment to advancing global health through science and education. She has achieved 119 citations, published 10 scientific documents, and holds an h-index of 5, reflecting her academic influence and research excellence.

Profiles: Scopus | Google Scholar

Featured Publications

1. Tombari, W., Nsiri, J., Larbi, I., Guerin, J. L., & Ghram, A. (2011). Genetic evolution of low pathogenicity H9N2 avian influenza viruses in Tunisia: . Acquisition of new mutations. Virology Journal, 8(1), 467.

2. Tombari, W., Paul, M., Bettaieb, J., Larbi, I., Nsiri, J., Elbehi, I., Gribaa, L., & Ghram, A. (2013). Risk factors and characteristics of low pathogenic avian influenza virus isolated from commercial poultry in Tunisia. PLoS ONE, 8(1), e53524.

3. Boudaoud, A., Mamache, B., Tombari, W., & Ghram, A. (2016). Virus mutations and their impact on vaccination against infectious bursal disease (Gumboro disease). Revue Scientifique et Technique, 35(3), 875–897.

4. Kallel Sellami, M., Zitouni, M., Tombari, W., Ben Ayed, M., Abida, O., Laadhar, L., et al. (2007). Anti-desmoglein-1 antibodies are prevalent in Tunisian patients with hydatidosis and leishmaniasis. British Journal of Dermatology, 156(3), 591–593.

Achilleas Livieratos | Infectious Diseases Vaccines | Best Researcher Award

Published on by Infectious

Dr. Achilleas Livieratos | Infectious Diseases Vaccines | Best Researcher Award

Medical Researcher | Stanford University | Greece

Dr. Achilleas Livieratos, PhD, MRSB, is a distinguished biomedical researcher whose work bridges immunology, infectious diseases, circadian biology, and artificial intelligence applications in health sciences. His research integrates advanced computational methods, including machine learning and multi-agent transformer frameworks, to enhance evidence generation, vaccine immunology, and drug safety analytics. He has published extensively in leading journals such as Vaccines, Pathogens, Viruses, eClinicalMedicine, and Value in Health, contributing to global understanding of immune response dynamics, precision medicine, and outcomes research. Notably, his development of MetaMind, an AI-driven framework for automated network meta-analyses, and his studies on circadian influences on influenza vaccine immunity have been recognized as groundbreaking contributions. His investigations into immune durability across respiratory viruses, including RSV, SARS-CoV-2, and influenza, as well as his exploration of alternative therapies for long COVID, have significantly advanced clinical and translational knowledge. As a lead collaborator with Stanford University and the University of California, San Francisco, Dr. Livieratos has directed international research initiatives on infectious disease modeling, biomarker discovery, and the application of AI in health outcomes research. His earlier work at the University of Oxford produced landmark discoveries in neurogenetics and circadian disruption, underpinning his multidisciplinary expertise. Through leadership in European Pharma and AI consortia, he continues to drive innovation in predictive health analytics and precision therapeutics, demonstrating an exceptional fusion of biomedical insight, computational innovation, and translational research impact.

Profiles : Google Scholar | Scopus

Featured Publication

Oliver, P. L., Sobczyk, M. V., Maywood, E. S., Edwards, B., Lee, S., Livieratos, A., et al. (2012). Disrupted circadian rhythms in a mouse model of schizophrenia. Current Biology, 22(4), 314–319.

Taylor, T. N., Potgieter, D., Anwar, S., Senior, S. L., Janezic, S., Threlfell, S., Ryan, B., et al. (2014). Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse. Neurobiology of Disease, 62, 193–207.

Wobst, H. J., Denk, F., Oliver, P. L., Livieratos, A., Taylor, T. N., Knudsen, M. H., et al. (2017). Increased 4R tau expression and behavioural changes in a novel MAPT-N296H genomic mouse model of tauopathy. Scientific Reports, 7(1), 43198.

Livieratos, A., Gogos, C., & Akinosoglou, K. (2024). Impact of prior COVID-19 immunization and/or prior infection on immune responses and clinical outcomes. Viruses, 16(5), 685.

Livieratos, A., Gogos, C., & Akinosoglou, K. (2024). Beyond antivirals: Alternative therapies for long COVID. Viruses, 16(11), 1795.